The FDA issued draft guidance on biosimilar product development. To date, there are no biosimilars in the U.S. market because they were considered “too complex” to include in the 1984 Hatch-Waxman legislation, which regulates the generic drug industry in America. ...
It’s easy to forget about the coffee that you bought one morning on your way to work or the 50 miles that you drove to a client site. Cash flow is the lifeblood of every single business no matter how large or small. Built for freelancers and “micro businesses,” Xero...
